Design Therapeutics
DSGN
60 hedge funds and large institutions have $773M invested in Design Therapeutics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 5 reducing their positions, and 5 closing their positions.
480% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 5
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
86% more capital invested
Capital invested by funds: $415M → $773M (+$358M)
15% more funds holding
Funds holding: 52 → 60 (+8)
14.14% more ownership
Funds ownership: 50.85% → 64.98% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.4M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$5.18M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$4.98M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.4M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.47M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.72M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$650K |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$219K |
DSGN Hedge Fund Activity: Q4 2021 in Review
60 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q4 2021, worth a combined $773M — up 86% from $415M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new DSGN positions and 5 closed out — a net gain of 8 holders — while 29 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $15.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $11.4M.
- 60 institutional investors held Design Therapeutics (DSGN) as of Q4 2021, up from 52 in Q3 2021.
- Funds reported $773M of Design Therapeutics stock for Q4 2021, up 86% quarter-over-quarter.
- 13 funds opened new Design Therapeutics positions in Q4 2021 and 5 closed out, a net change of +8 holders.
- The largest Design Therapeutics buyer in Q4 2021 was BlackRock, an estimated $15.5M added.
- The largest Design Therapeutics seller in Q4 2021 was T. Rowe Price Associates, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2021.